Compare Enbridge Inc (ENB) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enbridge Inc vs IDEXX Laboratories, Inc. — how do they compare? Enbridge Inc trades at $51.64 (market cap $112.62B), while IDEXX Laboratories, Inc. trades at $569.65 (market cap $46.22B). The key difference: Enbridge Inc is far larger — about 2.4× IDEXX Laboratories, Inc.'s market cap, and Enbridge Inc pays a 5.34% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| ENB | IDXX | |
|---|---|---|
Market Cap | $112.62B | $46.22B |
Sector | Energy | Health |
52-Week High | $58.04 | $766.68 |
52-Week Low | $45.23 | $526.44 |
Enterprise Value | $196.53B | $47.12B |
Dividend Yield | 5.34% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENB trades at $51.49, up 0.19% on the day, with a mixed technical picture showing bearish moving averages but oversold RSI levels. The company reported Q2 2026 EPS of $0.46, beating estimates of $0.43, and maintains a strong dividend yield with 31 consecutive years of increases. Revenue for 2025 reached $65.19B, with net income of $7.49B, though profit margins have fluctuated. Analyst consensus is evenly split between Buy and Hold ratings.
Outlook is stable with growth supported by a $41B project backlog and utility demand, but risks include regulatory challenges like pipeline disputes and high debt levels. The stock offers income appeal through dividends, yet faces headwinds from energy market volatility and legal uncertainties.
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enbridge Inc
Enbridge owns extensive midstream assets that transport hydrocarbons across the U.S. and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also owns and operates a regulated natural gas utility and Canada's largest natural gas distribution company. Finally, the firm has a small renewables portfolio primarily focused on onshore and offshore wind projects.
Read more on ENB →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
